.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

FYCOMPA Drug Profile

« Back to Dashboard
Fycompa is a drug marketed by Eisai Inc and is included in two NDAs. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-four patent family members in thirty-one countries.

The generic ingredient in FYCOMPA is perampanel. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the perampanel profile page.

Summary for Tradename: FYCOMPA

Patents:2
Applicants:1
NDAs:2
Suppliers / Packagers: see list1
Drug Prices: :see details

Pharmacology for Tradename: FYCOMPA

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
FYCOMPA
perampanel
TABLET;ORAL202834-001Oct 22, 2012RXNo6,949,571► subscribeYY ► subscribe
Eisai Inc
FYCOMPA
perampanel
TABLET;ORAL202834-005Oct 22, 2012RXNo8,772,497► subscribeY ► subscribe
Eisai Inc
FYCOMPA
perampanel
TABLET;ORAL202834-006Oct 22, 2012RXYes► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: FYCOMPA

Drugname Dosage Strength RLD Submissiondate
perampanelTablets2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mgFycompa10/24/2016

Non-Orange Book Patents for Tradename: FYCOMPA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,563,8111,2-dihydropyridine compounds, manufacturing method thereof and use thereof► subscribe
9,045,426Method for producing 1,2-dihydropyridine-2-one compound► subscribe
8,304,548Method for producing 1, 2-dihydropyridine-2-one compound► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FYCOMPA

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2006004100► subscribe
TaiwanI346660► subscribe
World Intellectual Property Organization (WIPO)0196308► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FYCOMPA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0Finland► subscribe
2013017Lithuania► subscribePRODUCT NAME: PERAMPANELUM; REGISTRATION NO/DATE: EU/1/12/776/001 - EU/1/12/776/016, 2012 07 23 EU/1/12/776/017 - EU1/12/776/023 20121029
C0074France► subscribePRODUCT NAME: PERAMPANEL, SEL DE CELUI-CI OU HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/776/001 20120723
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc